ORSENIX
Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. It is committed to transforming cancer treatment with innovative oral therapies that give patients the freedom to live their everyday lives.
ORSENIX
Industry:
Biotechnology Life Science Medical
Address:
Wilmington, Delaware, United States
Country:
United States
Status:
Active
More informations about "Orsenix" on Search Engine
Orsenix Company Profile - Office Locations, Competitors …
Orsenix is a clinical-stage biotech company focusing on oral therapies to treat cancer. It develops a capsule form of arsenic trioxide for acute promyelocytic leukemia and other …See details»
Orsenix LLC | CipherBio
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. At Orsenix, we …See details»
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression …See details»
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 Syros has made an upfront cash payment of $12 million to Orsenix. In addition, Orsenix is eligible to receive a $6 million regulatory milestone related to the development of SY-2101 in APL and...See details»
Syros Pharmaceuticals acquires Orsenix - 2020-12-07
Overview. Acquired Organization: Orsenix Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide. Acquiring Organization: Syros …See details»
Orsenix - The Pharma Letter
Orsenix. "Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers." "Our investigational ATO, ORH-2014, is a …See details»
Orsenix - Contacts, Employees, Board Members, …
Unlock even more features with Crunchbase Pro. Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide.See details»
Orsenix Presents Positive Final Phase 1 Study Results for Lead ...
Jun 18, 2019 WILMINGTON, DE / ACCESSWIRE / June 18, 2019 / Orsenix, LLC., a clinical stage biotech company committed to transforming cancer treatment with …See details»
Syros acquires clinical-stage drug candidate for acute …
Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly …See details»
Syros Acquires Clinical Candidate for the Treatment of …
December 7, 2020. Rare Daily Staff. Syros Pharmaceuticals has acquired Orsenix’ ORH-2014, a targeted clinical-stage drug candidate that has the potential to dramatically …See details»
Orsenix - Products, Competitors, Financials, Employees, …
People. About Orsenix. Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other …See details»
Syros acquires clinical-stage candidate for $12M; expects $90.5M …
Dec 6, 2020 Syros Pharmaceuticals ( NASDAQ: SYRS) acquires from Orsenix all of its assets related to SY-2101, formerly known as ORH-2014, an oral form of arsenic trioxide …See details»
Orsenix (SY-2101) Company Profile 2024: Valuation, Investors ...
Orsenix (SY-2101) Overview. Update this profile. Status. Acquired/ Merged. Latest Deal Type. Asset Purch. Financing Rounds. 1. General Information. Description. Portfolio of Intellectual property, clinical and preclinical data, the regulatory dossier and product inventory related to the development and commercialization of SY-2101.See details»
Orsenix LLC - BioCentury Company Profiles - BCIQ
Dec 8, 2020 Orsenix LLC - BioCentury Company Profiles for the biopharma industry. LOG IN. Analysis. Featured Analysis. Articles by Category. Current Editions. Data Graphics. …See details»
Syros acquires Orsenix’s SY-2102 drug candidate for APL treatment
Dec 9, 2020 In recent developments, Syros Pharmaceuticals, Inc, a Cambridge-headquartered biopharmaceutical organization that focuses on developing treatments for immune-related diseases as well as cancer, has reportedly acquired all assets associated with SY-2101, a novel oral form drug candidate of arsenic trioxide (ATO) from Orsenix, LLC.See details»
Syros Pharmaceuticals After The Orsenix Deal - Seeking Alpha
Dec 29, 2020 Healthcare. Syros Pharmaceuticals After The Orsenix Deal. Dec. 29, 2020 1:44 AM ET Syros Pharmaceuticals, Inc. (SYRS) Stock 5 Comments. 5 Likes. William Meyers. 7.54K Follower s. Summary. Syros...See details»
Organization | Orsenix LLC - CDEK
Orsenix LLC Report issue. For profit Phase 1. Founded: Wilmington DE United States (2014 ... Organization Overview. First Clinical Trial. 2016 NCT03048344. First Marketed …See details»
Orsenix Financials | Craft.co
Home. / Orsenix. / Financials. Overview. Locations. Financials. Operating Metrics. Human Capital. Key People. Competitors. Supplier Risk. Orsenix Financials. Orsenix does not have financial data available on financial statements or acquisitions and subsidiaries. CreditSafe Score. Orsenix Financials | Craft.co.See details»
Exposure to Arsenic: a major Public Health Concern
28 October 2019. | Publication. Download (99 kB) Overview. Soluble inorganic arsenic is highly acutely toxic. Intake of inorganic arsenic over a long period can lead to chronic …See details»
Martinelli's recalls apple juice sold at Target, Whole Foods over …
2 days ago Published April 30, 2024, 2:59 p.m. ET. Martinelli’s recalled one lot of its pricey apple juice being sold at major retailers across the US including Target, Whole Foods …See details»